Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail, KSA, Saudi Arabia.
Department of Pharmacy, Abbottabad University of Science and Technology, Havelian, Pakistan.
Folia Microbiol (Praha). 2021 Dec;66(6):897-916. doi: 10.1007/s12223-021-00926-5. Epub 2021 Oct 26.
Recent advancement in manipulation techniques of gut microbiota either ex vivo or in situ has broadened its plausible applicability for treating various diseases including cardiovascular disease. Several reports suggested that altering gut microbiota composition is an effective way to deal with issues associated with managing cardiovascular diseases. However, actual translation of gut microbiota manipulation-based techniques into cardiovascular-therapeutic approach is still questionable. This review summarized the evidence on challenges, opportunities, recent development, and future prospects of gut microbiota manipulation for targeting cardiovascular diseases. Initially, issues associated with current cardiovascular diseases treatment strategy, association of gut microbiota with cardiovascular disease, and its influence on cardiovascular drugs were discussed, followed by applicability of gut microbiota manipulation as a cardiovascular disease intervention strategy along with its challenges and future prospects. Despite the fact that the gut microbiota is rugged, interventions like probiotics, prebiotics, synbiotics, fecal microbiota transplantation, fecal virome transplantation, antibiotics, diet changes, and exercises could manipulate it. Advanced techniques like administration of engineered bacteriophages and bacteria could also be employed. Intensive exploration revealed that if sufficiently controlled approach and proper monitoring were applied, gut microbiota could provide a compelling answer for cardiovascular therapy.
近年来,无论是在体外还是原位操纵肠道微生物群的技术都取得了进步,这拓宽了其在治疗各种疾病(包括心血管疾病)方面的应用潜力。有几项报告表明,改变肠道微生物群的组成是解决与心血管疾病管理相关问题的有效方法。然而,将基于肠道微生物群操作的技术实际转化为心血管治疗方法仍然存在疑问。本综述总结了肠道微生物群操作靶向心血管疾病的挑战、机遇、最新进展和未来前景的证据。首先,讨论了与当前心血管疾病治疗策略相关的问题、肠道微生物群与心血管疾病的关联及其对心血管药物的影响,接着讨论了将肠道微生物群操作作为一种心血管疾病干预策略的适用性及其挑战和未来前景。尽管肠道微生物群具有很强的适应性,但可以通过益生菌、益生元、合生菌、粪便微生物群移植、粪便病毒群移植、抗生素、饮食改变和运动等方式对其进行干预。还可以采用像工程噬菌体和细菌的给药等先进技术。深入的探索表明,如果应用了足够的控制方法和适当的监测,肠道微生物群可以为心血管治疗提供一个有吸引力的答案。